Edgestream Partners L.P. Acquires New Holdings in DexCom, Inc. (NASDAQ:DXCM)

Edgestream Partners L.P. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 13,041 shares of the medical device company’s stock, valued at approximately $1,014,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Versant Capital Management Inc bought a new stake in shares of DexCom in the fourth quarter worth $25,000. Private Trust Co. NA grew its position in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the last quarter. Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth about $38,000. SBI Securities Co. Ltd. bought a new position in shares of DexCom during the fourth quarter worth about $49,000. Finally, Midwest Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth about $54,000. 97.75% of the stock is owned by institutional investors.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 45,083 shares of company stock valued at $3,826,604 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DXCM shares. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Stock Down 0.7 %

DXCM stock opened at $70.26 on Wednesday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average is $84.53 and its 200-day moving average is $76.98. The firm has a market capitalization of $27.46 billion, a PE ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.